Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 114

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 114
---
 bona fide
offering thereof.

| II-3 |

(8) Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.

(9) To
file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust
Indenture Act in accordance with the rules and regulations prescribed by the Securities and Exchange Commission under Section 305(b)(2)
of the Trust Indenture Act.

| II-4 |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form F-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
Cardiff, Wales on September 26, 2025.

| BIODEXA PHARMACEUTICALS PLC |                                                           |
| By:                         | /s/ Stephen Stamp                                         |
|                             | Name:  Stephen Stamp                                      |
|                             | Title:  Chief Executive Officer & Chief Financial Officer |

<div align='center'>POWER OF ATTORNEY AND SIGNATURES</div>

We, the undersigned officers
and directors of Biodexa Pharmaceuticals PLC hereby severally constitute and appoint Stephen Stamp and Stephen Parker, each in their individual
capacity, our true and lawful attorney with full power to sign for us and in our names in the